Black Diamond Therapeutics, Inc. (BDTX)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
1.74 USD
+0.06
(3.274%)
⇧
(Oct. 14, 2026, 1:03 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:49 a.m. EDT
Black Diamond Therapeutics presents a classic biotech dichotomy: a fundamentally distressed balance sheet with negative earnings and no dividend support clashes with aggressive analyst price targets and heavy speculative call buying. The company is technically trading below its 50-day and 200-day averages, reflecting a downtrend that has erased nearly 88% of its value over the last five years. While the recent quarterly results and progress in the silevertinib program have sparked a 'strong buy' recommendation from analysts, the underlying fundamentals remain precarious with significant cash burn and no revenue. The options market is pricing in a binary eventuality—a massive jump to the $5–$7 range—rather than a steady recovery. For investors, this is a high-risk speculation play dependent entirely on future clinical data rather than current financial health; the stock lacks the earnings power or yield to justify a traditional investment rating. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.171504 |
| AutoTheta | 0.184651 |
| AutoETS | 0.185121 |
| AutoARIMA | 0.185127 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.661 |
| Excess Kurtosis | -0.43 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.66 |
| Market Cap | 99,682,256 |
| Forward P/E | -1.74 |
| Beta | 3.33 |
| Website | https://www.blackdiamondtherapeutics.com |
As of Oct. 10, 2026, 9:49 a.m. EDT: Speculators are overwhelmingly bullish on upside potential, evidenced by massive open interest in out-of-the-money calls (strikes $2.50, $5.00, $7.50) compared to negligible put activity. The call volume at distant strikes suggests a 'lottery ticket' mentality hoping for a clinical trial breakthrough or catalyst-driven spike, while the lack of protective puts indicates traders are willing to take significant downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.59518075 |
| Address1 | 245 First Street |
| Address2 | 18th Floor |
| All Time High | 46.25 |
| All Time Low | 1.18 |
| Ask | 2.12 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 641,660 |
| Average Daily Volume3 Month | 616,064 |
| Average Volume | 616,064 |
| Average Volume10Days | 641,660 |
| Beta | 3.325 |
| Bid | 1.24 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.673 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.735 |
| Current Ratio | 7.284 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.76 |
| Day Low | 1.63 |
| Debt To Equity | 17.66 |
| Display Name | Black Diamond Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -44,349,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.067 |
| Enterprise Value | 2,986,295 |
| Eps Current Year | -0.56667 |
| Eps Forward | -1.0 |
| Eps Trailing Twelve Months | -0.75 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.9912 |
| Fifty Day Average Change | -0.25619996 |
| Fifty Day Average Change Percent | -0.12866612 |
| Fifty Two Week Change Percent | -59.518074 |
| Fifty Two Week High | 4.94 |
| Fifty Two Week High Change | -3.205 |
| Fifty Two Week High Change Percent | -0.6487854 |
| Fifty Two Week Low | 1.6 |
| Fifty Two Week Low Change | 0.13499999 |
| Fifty Two Week Low Change Percent | 0.084374994 |
| Fifty Two Week Range | 1.6 - 4.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,580,481,000,000 |
| Float Shares | 52,511,576 |
| Forward Eps | -1.0 |
| Forward P E | -1.735 |
| Free Cashflow | -23,577,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 21 |
| Fullday Change | 0.055000067 |
| Fullday Change Percent | 3.2738135 |
| Fullday Price | 1.735 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0066299997 |
| Held Percent Institutions | 0.72587997 |
| Implied Shares Outstanding | 57,453,747 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Black Diamond Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 99,682,256 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_424913244 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -42,555,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 109,162,119 |
| Number Of Analyst Opinions | 7 |
| Open | 1.64 |
| Operating Cashflow | -32,837,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 252 0848 |
| Previous Close | 1.68 |
| Price Eps Current Year | -3.0617468 |
| Price Hint | 4 |
| Price To Book | 1.0370592 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 6.975 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.055000067 |
| Regular Market Change Percent | 3.2738135 |
| Regular Market Day High | 1.76 |
| Regular Market Day Low | 1.63 |
| Regular Market Day Range | 1.63 - 1.76 |
| Regular Market Open | 1.64 |
| Regular Market Previous Close | 1.68 |
| Regular Market Price | 1.735 |
| Regular Market Time | 1,791,997,396 |
| Regular Market Volume | 501,524 |
| Return On Assets | -0.19112 |
| Return On Equity | -0.37215 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 57,453,747 |
| Shares Percent Shares Out | 0.083100006 |
| Shares Short | 4,775,586 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,119,016 |
| Short Name | Black Diamond Therapeutics, Inc |
| Short Percent Of Float | 0.1195 |
| Short Ratio | 8.17 |
| Source Interval | 15 |
| State | MA |
| Symbol | BDTX |
| Target High Price | 14.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 110,506,000 |
| Total Cash Per Share | 1.923 |
| Total Debt | 16,970,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.242275 |
| Two Hundred Day Average Change | -0.507275 |
| Two Hundred Day Average Change Percent | -0.22623228 |
| Type Disp | Equity |
| Volume | 501,524 |
| Website | https://www.blackdiamondtherapeutics.com |
| Zip | 2,142 |